Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - capsule, hard - excipient ingredients: indigo carmine; purified talc; gelatin; iron oxide red; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

United States - English - NLM (National Library of Medicine)

butler animal health supply, llc dba covetrus north america - atipamezole hydrochloride (unii: 2w4279571x) (atipamezole - unii:03n9u5jaf6) - atipamezole hydrochloride injection is indicated for the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs. since atipamezole is always used concomitantly with dexmedetomidine or medetomidine, it should not be used in dogs with the following conditions: cardiac disease, respiratory disorders, liver or kidney diseases, dogs in shock, severely debilitated dogs, or dogs stressed due to extreme heat, cold or fatigue. administration of atipamezole is contraindicated in dogs with a known hypersensitivity to the drug.

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - benserazide hcl; levodopa - capsule - 28.5mg - benserazide hcl 28.5mg; levodopa 100mg

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - benserazide hcl 28.5mg equivalent to benserazide; levodopa - capsule - 25 mg - benserazide hcl 28.5mg equivalent to benserazide 25 mg; levodopa 100 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

eurovet animal health b.v. - atipamezole hydrochloride - solution for injection - 5.0 milligram(s)/millilitre - atipamezole - cats, dogs - neurological preparations

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg); levodopa, quantity: 100 mg - capsule, hard - excipient ingredients: mannitol; indigo carmine; iron oxide yellow; hypromellose; titanium dioxide; magnesium stearate; purified talc; gelatin; hydrogenated vegetable oil; povidone; calcium hydrogen phosphate dihydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; iron oxide red; ethanol absolute; potassium hydroxide; ammonia - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism. madopar hbs is indicated for patients presenting with all types of fluctuations in response (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 200 mg; benserazide hydrochloride, quantity: 57 mg (equivalent: benserazide, qty 50 mg) - capsule, hard - excipient ingredients: iron oxide yellow; magnesium stearate; indigo carmine; povidone; gelatin; titanium dioxide; purified talc; microcrystalline cellulose; iron oxide red - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 50 mg; benserazide hydrochloride, quantity: 14.25 mg (equivalent: benserazide, qty 12.5 mg) - capsule, hard - excipient ingredients: indigo carmine; iron oxide black; magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; povidone; mannitol; gelatin - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

United States - English - NLM (National Library of Medicine)

orion corporation - atipamezole hydrochloride (unii: 2w4279571x) (atipamezole - unii:03n9u5jaf6) - atipamezole hydrochloride 5 mg in 1 ml - antisedan is indicated for the reversal of the sedative and analgesic effects of dexdomitor (dexmedetomidine hydrochloride), and domitor (medetomidine hydrochloride) in dogs. since atipamezole is always used concomitantly with dexmedetomidine or medetomidine, it should not be used in dogs with the following conditions: cardiac disease, respiratory disorders, liver or kidney diseases, dogs in shock, severely debilitated dogs, or dogs stressed due to extreme heat, cold or fatigue. administration of atipamezole is contraindicated in dogs with a known hypersensitivity to the drug.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

dechra regulatory b.v. - atipamezole hydrochloride 5 mg/ml - eq. atipamezole 4,27 mg/ml - solution for injection - 5 mg/ml - atipamezole hydrochloride 5 mg/ml - atipamezole - dog; cat